Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panzytrat 25,000 versus placebo for pancreatic exocrine insufficiency
2004-002468-89Phase 4Completed
- Sponsor
- Axcan Pharma Inc.
- Start
- Sep 2004
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in exocrine pancreatic insufficiency (EPI) and chronic pancreatitis (CP) comparing Panzytrat 25,000 with Placebo (2 arms). Started Sep 2004; status: completed.
02
Drugs
pancrelipase
03
Conditions
exocrine pancreatic insufficiency (EPI)chronic pancreatitis (CP)
Beyond the preview
Go deeper on 2004-002468-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002468-89.